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BACKGROUND: Diagnosis with prostate cancer has been reported to increase the risk of subsequent tumours. However, specific data
on individuals with a parental history are not available so far.
METHODS: On the basis of the nationwide Swedish Family-Cancer Database including 18,207 primary invasive prostate cancers,
standardised incidence ratios (SIRs) were used to estimate the relative risks of subsequent tumours after prostate cancer in the
general population and among individuals with a parental history of cancer.
RESULTS: A significantly increased SIR of colorectal cancer was found among prostate cancer patients with a parental history of
colorectal cancer (2.26, 11 cases). The SIRs of parental concordant (same site) tumours after prostate cancer were also increased for
urinary bladder cancer (4.42, 4 cases) and chronic lymphoid leukaemia (38.0, 2 cases).
CONCLUSION: A higher than additive and multiplicative interaction was observed between the individual history of prostate cancer and
parental history of colorectal and urinary bladder cancers, although the number of cases did not permit the rejection of any
interaction model. The results suggest that the occurrence of second tumours, for example bladder after prostate or prostate after
bladder tumours, is mostly related to shared genetic and non-genetic risk factors rather than treatment of first cancer.
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Prostate cancer is the most common cancer among males in
Sweden, with an incidence rate up to 214 per 100000 person-years
(Centre for Epidemiology, 2006). The incidence of prostate cancer
in Sweden has experienced an annual increase of 3.7% during the
last decade. With the improvement in survival from prostate
cancer, more and more survivors might face the problem of having
an increased risk for subsequent primary tumours (Travis, 2006;
Travis et al, 2006). An increased risk of subsequent prostate cancer
after other types of cancer has been also observed (Dong and
Hemminki, 2001; Diener-West et al, 2005; Sørensen et al, 2005;
Neuzillet et al, 2007). For example, the within-patient clustering of
bladder and prostate tumours has been extensively explored
(Chun, 1997; Kouriefs et al, 2005; Liauw et al, 2006; Bostrom and
Soloway, 2007; Kellen et al, 2007; Bostrom et al, 2008; Singh et al,
2008). The plausible aetiology of multiple subsequent tumours
could be the effect of therapy, genetic and non-genetic risk factors,
or the interactions between them (Hemminki and Boffetta, 2004;
Travis, 2006; Travis et al, 2006). Aetiological studies have mostly
focused on therapy-related factors, particular radiotherapy (Brenner,
2006; Kendal et al, 2006; Subramanian et al, 2007; Bostrom and
Soloway, 2007). However, radiotherapy does not completely
explain the increased risk of second tumours and limited
information is available on the potential effect of family history
on the risk of subsequent tumours after prostate cancer (Singh
et al, 2008).
This study investigates the role of parental history in the
development of second malignancies after prostate cancer, and the
risk of subsequent prostate cancer in familial cases using the 2006
update of the nationwide Swedish Family-Cancer Database.
Although cancer is mainly induced by environmental factors and
only a small proportion can be explained by established genes,
population-based estimation of parental risks is still a good
measure of the familial clustering of tumours and reflects the sum
of genetic risk effects attributable to both known and unknown
genes.
MATERIALS AND METHODS
The nationwide Swedish Family-Cancer Database includes off-
spring born in Sweden since 1932 and also their biological parents,
with information about the first and second primary malignancies
they experienced. Cancer was recorded according to the 7th
version of the ICD code (ICD-7), and verified by the cytological or
histological code. The agreement between clinical and cytological
or histological diagnosis is close to 100% (Centre for Epidemio-
logy, 2006). Unfortunately, information about cancer treatment is
not included in the Swedish Cancer Registry.
Parental risks were investigated when fathers were affected by
prostate tumour and when parents were affected by concordant
(same site) cancer. On the basis of the Swedish Family-Cancer
Database, the relative risk of second tumours in the general
population and among individuals with a family history was
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sestimated by standardised incidence ratios (SIRs), calculated
as the ratio of the observed (O) to expected (E) number of cases.
The follow-up started at diagnosis of prostate cancer and ended at
the occurrence of death, emigration, the diagnosis of any
subsequent malignancy or on 31 December 2004 (end of the
study). Cases and person-years were classified according to the
categories age (5-year groups), region (4 regions), calendar period
(9 intervals) and socioeconomic status (6 groups). Confidence
intervals (95% CI) were calculated assuming a Poisson distribution
of the observed number of cases. To evaluate the risk of a second
prostate cancer after any cancer, follow-up began at the date of
diagnosis of the first malignancy and the uncensored event was the
diagnosis of prostate cancer. Multiplicative interaction indexes
(MIIs) and interaction contrast ratios (ICRs) were used to
investigate the possible interaction between ‘individual history of
prostate’ and ‘parental history of cancer’. If SIRprostate represents
the relative risk of cancer after prostate cancer, SIRfh represents
the relative risk among individuals with a parental history and
SIRprostatexfh represents the relative risk in prostate cancer patients
with a parental history, MII¼SIRprostatexfh/(SIRprostate SIRfh) and
ICR¼SIRprostatexfh SIRprostate SIRfhþ1. MIIa1 indicates a
departure from multiplicativity and ICRa0 suggests a departure
from additivity. Confidence intervals and P-values for MII and ICR
were calculated by bootstrapping based on 100000 replications. All
analyses were carried out in SAS 9.1, the SAS Institute, Cary, NC, USA.
RESULTS
A total of 3818429 male offspring were registered and 18207 men
were diagnosed with prostate cancer from 1978 to 2004 in Sweden.
Among them, 560 experienced a second malignancy after
diagnosis; 75269 men were diagnosed with any tumour other
than prostate cancer and 838 of them had a subsequent prostate
cancer.
The relative risk of cancer after prostate cancer is shown in
Table 1 for sites with at least 11 observed subsequent cases (the
same sites are shown in Table 2). Compared with the general
Swedish population, prostate cancer patients showed an increased
risk of cancer in the kidney (SIR: 1.75), urinary bladder (1.83) and
skin (squamous cell, 1.67). The increased risk of colorectal cancer
(1.23) showed borderline significance. Among patients with a
parental history of prostate cancer, the risk was increased for
bladder (2.44) and skin squamous cell cancers (3.34) and for
myeloma (3.85). The third column of Table 1 shows the relative
risks of second cancer in prostate cancer patients with a parental
family history of concordant (same site) cancer. Prostate cancer
patients with a parental history of colorectal cancer showed a 2.23
times higher risk of colorectal cancer than did men in the general
population. Increased familial risks were also observed for urinary
bladder (SIR: 4.42) and chronic lymphoid leukaemia (38.0,
2 familial cases affected after prostate cancer). As a control, the
parental risk of these cancers as first primary was also shown in
the fourth column.
Table 2 provides the risk of prostate cancer as second tumour.
Increased risks were detected for kidney (1.56) and urinary
bladder (2.25) cancer and for melanoma (1.22). In patients with a
paternal history of prostate cancer, a significantly increased risk
was observed for colorectal (1.88), renal (3.92) and urinary bladder
(3.97) cancers. Among patients with a family history of concordant
cancer, only by urinary bladder cancer showed a significantly
increased risk after prostate cancer. It is important to point out
here that urinary bladder cancer always showed a positive
association with prostate cancer, both as first and as second
primary tumour, both in the general population and among
individuals with a family history.
Table 3 explores the interaction between the individual history
of prostate cancer and family history of concordant cancer. For
colorectal, urinary bladder and skin cancers, the interaction
seemed to be higher than additive and higher than multiplicative.
By contrast, a lower than additive and lower than multiplicative
interaction was found for kidney cancer. However, the number of
cases was small and it did not permit the rejection of any
interaction model at the 5% confidence level.
DISCUSSION
This study focused on the effect of parental history of cancer on
the development of subsequent tumours after prostate cancer, and
on the risk of prostate cancer in cancer patients.
The Swedish Family-Cancer Database relies on national
registries of complete coverage, thus minimising biases due to
recall and ascertainment (Hemminki et al, 2001, 2006). Parents are
Table 1 Relative risks of second cancer after prostate tumours and familial risks of first primary cancer
Risk of second cancer after prostate cancer
Male offspring
Sons of men with
prostate cancer
Sons of patients affected by
concordant cancer
Familial risk of first primary
concordant cancer
Type of second cancer N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
Upper aerodigestive tract 12 0.88 0.45 1.54 2 0.96 0.09 3.54 1 10.16 0.00 58.2 49 1.67 1.26 2.22
Stomach 18 1.23 0.73 1.95 1 0.47 0.00 2.70 0 131 1.67 1.40 1.99
Colorectum 92 1.23 0.99 1.51 6 0.54 0.20 1.19 11 2.26 1.12 4.06 1573 1.69 1.61 1.78
Pancreas 17 1.24 0.72 1.99 1 0.49 0.00 2.82 0 85 2.01 1.62 2.50
Lung 63 1.15 0.88 1.47 6 0.74 0.27 1.63 2 1.15 0.11 4.21 647 1.72 1.58 1.86
Prostate 18 0.05 0.03 0.09 4 0.08 0.02 0.22 4 0.08 0.02 0.22 2472 1.88 1.80 1.96
Kidney 33 1.75 1.20 2.46 2 0.71 0.07 2.61 1 2.72 0.00 15.6 119 2.19 1.82 2.62
Urinary bladder 76 1.83 1.44 2.30 15 2.44 1.36 4.03 4 4.42 1.15 11.4 279 1.79 1.58 2.01
Melanoma 24 0.93 0.59 1.38 5 1.22 0.39 2.87 0 438 2.44 2.22 2.68
Skin, squamous cell 37 1.67 1.18 2.31 11 3.34 1.66 6.00 2 4.42 0.42 16.3 172 2.03 1.74 2.36
Nervous system 25 1.47 0.95 2.17 3 1.14 0.22 3.39 0 257 1.69 1.50 1.92
Non-Hodgkin’s lymphoma 33 1.44 0.99 2.03 2 0.58 0.05 2.13 1 3.24 0.00 18.6 167 1.86 1.60 2.17
Myeloma 14 1.61 0.88 2.71 5 3.85 1.22 9.06 1 11.7 0.00 67.0 35 2.43 1.74 3.40
Leukaemia 16 0.88 0.50 1.44 3 1.11 0.21 3.28 2 6.80 0.64 25.0 150 1.87 1.58 2.19
Chronic lymphoid leukaemia 8 0.97 0.43 1.93 3 2.46 0.46 7.29 2 38.0 3.58 140 46 6.11 4.47 8.15
Any type 560 0.72 0.66 0.78 79 0.69 0.54 0.86 305 0.80 0.69 0.87 81548 1.05 1.05 1.06
Abbreviations: CI¼confidence interval; N¼number of individuals with second neoplasm; SIR¼standardised incidence ratio. Bold refers to a significant risk increase with 5%
statistical significance.
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sregistered at the time of birth of the child, thus allowing tracking of
‘biological’ parents in spite of divorce and remarriage. The study
was limited because the maximum age in the offspring generation
was 72 years, still below the highest risk for most cancer types, thus
resulting in small numbers of familial cases. Moreover, no
individual information on treatment or other potential cancer risk
factors was available.
In this study, prostate cancer patients showed an increased risk
of second tumours in the urinary bladder, kidney and skin
(squamous cell). Patients affected by kidney and urinary bladder
cancers, and by melanoma, showed an increased risk of
subsequent prostate cancer. Novel data were related to the risk
of second tumours in prostate cancer patients with a parental
history of same-site tumours, which showed increased risks of
colorectal (SIR¼2.26) and urinary bladder (SIR¼4.42) cancers
and of chronic lymphoid leukaemia (SIR¼38.0).
Cancer treatment with radiation and chemotherapy has been
related to the development of second malignancies. Since 1980,
surgery, hormonal therapy and radiotherapy have been widely
used to treat prostate cancer. Chemotherapy has not been applied.
It has been shown that prostate cancer patients undergoing
external beam radiation therapy have a higher risk of secondary
cancer than do surgically treated patients and patients treated
with other forms of radiation (Neugut et al, 1997; Brenner, 2000,
2006; Baxter et al, 2005; Brenner and Hall, 2006; Moon et al, 2006).
The potential contribution of radiotherapy to the development of
second tumours should be reflected in an increasing risk with
increasing time after first diagnosis. However, additional
analyses of the database revealed decreasing risks with lead time
between the two diagnoses, which would limit the role of
radiotherapy in the development of subsequent tumours (data
not shown).
In this study, 15–20% of patients with second urinary bladder
or prostate cancer had a concordant parental history. The familial
risk of second bladder cancer after prostate cancer (4.42) was
higher than the relative risk of bladder cancer after prostate cancer
(1.83) and higher than the familial risk of bladder cancer (1.79).
Theoretically, a family history of cancer may lead to a more intense
screening of prostate cancer. Previous analyses from the database
found no increased risk of prostate cancer shortly after a paternal
prostate cancer diagnosis and a borderline risk (P¼0.07) after
diagnosis of a brother (Bermejo and Hemminki, 2005). The
absence of increased familial risks shortly after first diagnosis
suggests a contribution of genetic factors rather than intensified
medical attention.
On the basis of the independent effects of individual history of
prostate cancer and family history of urinary bladder cancer and
assuming an additive interaction model, the ICR would be
4.42 1.83 1.79þ1¼1.80 (Table 3). Analogously, the results
suggested a higher than multiplicative interaction between the
individual history of prostate cancer and family history of bladder
cancer, but the number of familial cases was small to rule out other
interaction models. Hardly any susceptibility genes are known that
would explain shared effects in prostate and bladder cancers.
Table 2 Relative risks of prostate tumours as second cancer in the general population and among individuals with a family history
Risk of second prostate cancer
Male offspring
Sons of men with
prostate cancer
Sons of patients affected by
concordant cancer
Type of first primary cancer N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
Upper aerodigestive tract 24 0.84 0.54 1.26 6 2.64 0.95 5.79 0
Stomach 14 1.00 0.54 1.68 2 2.19 0.21 8.05 1 1.26 0.00 7.24
Colorectum 92 0.80 0.65 0.99 16 1.88 1.07 3.07 6 0.49 0.18 1.08
Pancreas 2 0.32 0.03 1.17 0 0
Lung 19 0.52 0.31 0.91 2 0.76 0.07 2.78 2 0.89 0.08 2.29
Prostate 18 0.05 0.03 0.09 4 0.08 0.02 0.22 4 0.08 0.02 0.22
Kidney 56 1.56 1.18 2.03 14 3.92 2.14 6.60 1 1.14 0.00 6.53
Urinary bladder 203 2.25 1.95 2.58 30 3.97 2.68 5.67 11 2.85 1.42 5.12
Melanoma 111 1.22 1.01 1.47 11 1.57 0.78 2.82 3 1.51 0.29 4.48
Skin, squamous cell 45 1.08 0.79 1.45 7 2.04 0.81 4.23 2 0.98 0.90 3.61
Nervous system 44 1.15 0.83 1.54 3 0.92 0.17 2.72 0
Non-Hodgkin’s lymphoma 35 0.74 0.52 1.03 5 1.33 0.42 3.14 1 0.70 0.00 4.00
Myeloma 8 0.63 0.27 1.25 2 1.92 0.18 7.04 0
Leukaemia 24 0.79 0.51 1.18 4 1.70 0.44 4.41 1 1.05 0.00 6.01
Chronic lymphoid leukaemia 9 0.61 0.28 1.17 1 1.06 0.00 6.06 0
Any type 856 0.79 0.74 0.85 129 1.20 1.00 1.42 471 0.89 0.81 1.00
Abbreviations: CI¼confidence interval; N¼number of individuals with second neoplasm; SIR¼standardised incidence ratio. Bold refers to a significant risk increase with 5%
statistical significance.
Table 3 Interaction between individual history of prostate cancer and family history of concordant cancer
Type of interaction
Individual history Family history Individual and family history Additive Multiplicative
Type of second cancer N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) ICR (95% CI) P-value MII (95% CI) P-value
Colorectum 92 1.23 0.99 1.51 1573 1.69 1.61 1.78 11 2.26 1.12 4.06 0.34  0.78 2.40 0.68 1.09 0.55 2.15 0.59
Kidney 33 1.75 1.20 2.46 119 2.19 1.82 2.62 1 2.72 0.00 15.6  0.27  3.22 104 0.48 0.70 0.02 28.8 0.43
Urinary bladder 76 1.83 1.44 2.30 279 1.79 1.58 2.01 4 4.42 1.15 11.4 1.80  1.28 11.2 0.81 1.35 0.42 4.35 0.69
Skin, squamous cell 37 1.67 1.18 2.31 172 2.03 1.74 2.36 2 4.42 0.42 16.3 1.70  2.12 24.9 0.70 1.30 0.20 8.52 0.61
Abbreviations: CI¼confidence interval; ICR¼ interaction contrast Ratio; MII¼multiplicative interaction index; N¼number of individuals with second neoplasm; P¼probability
value for ICR larger than 0 and MII larger than 1; SIR¼standardised incidence ratio. Bold refers to a significant risk increase with 5% statistical significance.
Prostate cancer as a first and second cancer
H Zhang et al
937















sFor second chronic lymphoid leukaemia after prostate cancer, it
is difficult to explain the increased risks for a concordant parental
cancer history, as no germline mutation has been identified so far
(Sellick et al, 2005). Another new finding was the increased risks
for skin squamous cell carcinoma after prostate cancer, when the
offspring had a parental history of prostate cancer. Moreover, the
MII suggested a higher than multiplicative interaction between the
individual history of prostate cancer and family history of skin
squamous cell carcinoma.
A family history of prostate cancer seems to have an important
role in developing a second prostate cancer after any cancer
other than prostate cancer, with an estimated SIR of 1.20. In
addition to the candidate genes suggested earlier, a large number
of low-risk variants have been associated with prostate cancer in
genome-wide association studies (Dong, 2006; Eeles et al, 2008;
Gudmundsson et al, 2008; Thomas et al, 2008). The interaction
between family history and identified polymorphisms on prostate
cancer risk has been investigated recently (Zheng et al, 2008).
However, the present results indicate the association among
discordant cancer sites, and the effects of most recently identified
variants on colorectal, bladder and renal cancer have not been
investigated yet.
On the basis of the Swedish Family-Cancer database, our results
suggest that prostate cancer patients with a family history of
cancer have an increased risk of concordant tumours in the
urinary bladder. The increased risk in both directions – bladder
after prostate and prostate after bladder tumours – points to the
contribution of shared genetic and non-genetic risk factors.
Although the number of parental cases was small, the data suggest
that family history also seems to have an effect on other types of
concordant cancers.
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